<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

1   Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.

2   Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.

 

Discover the infinite power of partnership to drive scientific discovery

Crown Bioscience is a Contract Research Organization (CRO) driven by our mission is to empower our customers to improve human health.

We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.

Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.

Latest News

Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening

Read More

Oncology Databases

Quickly Find Models to Fit Your Research Needs

Learn More

Learn more about our services

Therapeutic Areas

Leverage our extensive experience in oncology and immuno-oncology

Learn More

Model Systems

Discover the largest commercially available collection of PDX models as well as our novelin vitro models

Learn More

Technologies

Utilize our bioinformatics, biomarker analysis, genomics and high content imaging services to advance your preclinical studies

Learn More

Service Types

Accelerate your drug development with our biomarker discovery, efficacy testing, DMPK and pharmacology services

Learn More

Industry-leading Customer Experience

Data Below Represents Q3 2023

Studies <br>Completed

Studies
Completed

This data point indicates the total number of studies in Q2 2023 that the CSAT, Customer Effort, and Customer Expectation scores are measured against.

Studies
Completed

1662

Customer <br>Satisfaction

Customer
Satisfaction

Also known as CSAT, this metric indicates how satisfied customers are with the complete Crown Bioscience customer experience.

Customer
Satisfaction

98%

Customer <br>Effort

Customer
Effort

The Customer Effort Score (CES) is a metric that measures how easy it was to work with Crown Bioscience.

Customer
Effort

92%

Customer <br>Expectation

Customer
Expectation

This metric indicates the strength of Crown Bioscience in meeting or exceeding customer expectations.

Customer
Expectation

98%

Explore our monthly Customer Satisfaction Report

Review our published work!

Indivumed Services

Market Leading Multi-Omics Grade Biospecimens

LEARN MORE

Latest Blog Posts

November 21, 2023

Exploring the Future of Drug Combinations: A Deep Dive into In Vivo Synergy Research in Mouse Tumor Models

The world of oncology is ever-evolving, and as researchers and scientists, we are perpetually on the front lines searching for innovative solutions against cancer. One promising direction is the exploration of drug combinations. The idea is both simple and profound: what if we could combine two or more drugs, amplifying their effects to produce outcomes greater than their individual impacts? Welcome to the world of drug synergy!

Read

November 17, 2023

Fatty Acid Degradation (FAD) Subtypes of HCC PDX Models Accurately Recapitulate Anti-Cancer Drug Sensitivity in Patients

Liver cancer remains a major health burden in the U.S. and globally, with incidence rates continuing to rise. Estimates indicate that liver cancer will affect more than 1 million individuals annually in coming years. Hepatocellular carcinoma (HCC), the predominant form that accounts for roughly 90% of primary liver cancer cases, is highly complex and heterogeneous and is often associated with underlying chronic liver disease, such as hepatitis.

Read

October 30, 2023

PDOs, PDXOs, or PDXs? Selecting the Best Model to Progress Your Patient-Centric Research

Selecting the right preclinical model to evaluate a drug candidate’s mechanism of action and efficacy can be challenging given the wide variety of available options and their associated time and cost investments. However, selecting the appropriate model can mean the difference between success and failure for a given drug candidate. 3D in vitro organoids are powerful predictive preclinical models that are ideal for bridging the gap between traditional 2D in vitro cell lines and in vivo studies because they offer a more clinically relevant platform than 2D cell lines prior to transitioning to more costly and time-consuming in vivo validation studies.

Read

October 30, 2023

Publication Spotlight: DSP vs. Visium: A Comparative Study in Spatial Transcriptomics for Cancer Research

Dr. Alexander Swarbrick's recent paper on bioRxiv, titled "An experimental comparison of the Digital Spatial Profiling and Visium spatial transcriptomics technologies for cancer research" delves into a comparative analysis of the DSP and Visium platforms. While both technologies displayed commendable prowess in spatially profiling breast cancer tissues, they shine in distinct areas of application.

Read

Ensuring that every patient has the right
treatment at the right time.